A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

被引：0
|
作者：
Phiri, Kelesitse [1 ]
Hallas, Jesper [2 ]
Linder, Marie [3 ]
Margulis, Andrea [4 ]
Suehs, Brandon [5 ]
Arana, Alejandro [4 ]
Bahmanyar, Shahram [3 ]
Enger, Cheryl [1 ]
Horter, Libby [5 ]
Odsbu, Ingvild [3 ]
Olesen, Morten [2 ]
Perez-Gutthann, Susana [4 ]
Kristiansen, Nina Sahlertz [2 ]
Appenteng, Kwame [6 ]
de Vogel, Stefan [7 ]
Seeger, John [1 ]
机构：
[1] Optum, Boston, MA USA
[2] Univ Southern Denmark, Odense, Denmark
[3] Karolinska Inst, Stockholm, Sweden
[4] RTI Hlth Solut, Barcelona, Spain
[5] Humana Healthcare Res, Louisville, KY USA
[6] Astellas Pharma US, Northbrook, IL USA
[7] Astellas Pharma BV, Leiden, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4352
引用
收藏
页码：465 / 465
页数：1
相关论文
共 50 条
  • [1] A STUDY OF CANCER OCCURRENCE IN USERS OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS FOR OVERACTIVE BLADDER
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    JOURNAL OF UROLOGY, 2020, 203 : E910 - E911
  • [2] A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Hoffman, Veena
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 867 - 877
  • [3] Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
    Veena Hoffman
    Jesper Hallas
    Marie Linder
    Andrea V. Margulis
    Brandon T. Suehs
    Alejandro Arana
    Kelesitse Phiri
    Cheryl Enger
    Libby Horter
    Ingvild Odsbu
    Morten Olesen
    Susana Perez-Gutthann
    Yihua Xu
    Nina Sahlertz Kristiansen
    Kwame Appenteng
    Stefan de Vogel
    John D. Seeger
    Drug Safety, 2021, 44 : 899 - 915
  • [4] Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
    Hoffman, Veena
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea V.
    Suehs, Brandon T.
    Arana, Alejandro
    Phiri, Kelesitse
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Xu, Yihua
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John D.
    DRUG SAFETY, 2021, 44 (08) : 899 - 915
  • [5] Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings From a Non-interventional, Real-world Data Safety Study
    Hoffman, Veena
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon T.
    Arana, Alejandro
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Gutthann, Susana Perez
    Xu, Yihua
    Kristiansen, Nina S.
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John D.
    CIRCULATION, 2020, 142
  • [6] Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: Findings from a non-interventional, real-world data safety study
    Hoffman, Veena
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea V.
    Suehs, Brandon T.
    Arana, Alejandro
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Xu, Yihua
    Kristiansen, Nina S.
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 85 - 85
  • [7] Cancer Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers
    Linder, Marie
    Margulis, Andrea V.
    Anveden-Berglind, Ingegard
    Bahmanyar, Shahram
    Bui, Christine L.
    Atsma, Willem Jan
    Appenteng, Kwame
    Franks, Billy
    de Vogel, Stefan
    D'Silva, Milbhor
    Perez-Gutthann, Susana
    Arana, Alejandro
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 535 - 535
  • [8] Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
    Carlson, Kevin V.
    Rovner, Eric S.
    Nair, Kavita V.
    Deal, Anna S.
    Kristy, Rita M.
    Hairston, John C.
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2021, 13 (04) : 425 - 434
  • [9] Cost and resource utilization in frail patients with overactive bladder treated with mirabegron or an antimuscarinic
    Walker, D.
    Johnson, T. M.
    Kimura, T.
    Nimke, D.
    Jiang, B.
    Lozano-Ortega, G.
    Lockefeer, A.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S140 - S140
  • [10] ECONOMIC EVALUATION OF MIRABEGRON VERSUS ANTIMUSCARINIC TREATMENTS IN PATIENTS WITH OVERACTIVE BLADDER FROM THE PESPECTIVE OF THE SPANISH NATIONAL HEALTH SERVICE
    Toledo, A.
    Alvarez-Novoa, I
    Mora, A.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    Nazir, J.
    VALUE IN HEALTH, 2015, 18 (07) : A510 - A511
12345